Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)

European Neuropsychopharmacology

Volumn 20, Issue 5, 2010, Pages 310-316

  Gaebel, Wolfgang ^a   Riesbeck, Mathias ^a   von Wilmsdorff, Martina ^a   Burns, Tom ^b   Derks, Eske M ^c   Kahn, René S ^c   Rössler, Wulf ^d   Fleischhacker, W Wolfgang ^e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Drug attitude; ; Effectiveness; ; First episode; ; Predictor; Schizophrenia; ; Treatment discontinuation;

Indexed keywords

AMISULPRIDE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; ZIPRASIDONE;

AKATHISIA; ARTICLE; CLINICAL EVALUATION; DRUG ATTITUDE INVENTORY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PARKINSONISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEXUAL DYSFUNCTION; TREATMENT DURATION; VALIDITY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; FEMALE; HALOPERIDOL; HUMANS; MALE; MEDICATION ADHERENCE; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; ROC CURVE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE; THIAZOLES; TREATMENT OUTCOME;

EID: 77950296414     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.02.001     Document Type: Article

References (32)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. De Haan L., van Amelsvoort T., Dingemans P., Linszen D. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. Pharmacopsychiatry 2007, 40:264-268.
3. Dolder C.R., Lacro J.P., Warren K.A., Golshan S., Perkins D.O., Jeste D.V. Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. J. Clin. Psychopharmacol. 2004, 24:404-409.
4. Fleischhacker W.W., Keet I.P., Kahn R.S. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr. Res. 2005, 78:147-156.
5. Gerlach J., Korsgaard S., Clemmesen P., et al. The St Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 1993, 87:244-252.
6. Guy W. Clinical Global Impressions (CGI) Scale. ECDEU Assessment Manual for Psychopharmacology, revised 1976, 218-222. US Dept Health, Education, and Welfare, Washington, DC.
7. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 1983, 13:177-183.
8. Hogarty G.E., Schooler N.R., Baker R.W. Efficacy versus effectiveness. Psychiatr. Serv. 1997, 48:1107.
9. Hsiao J.K., Bartko J.J., Potter W.Z. Diagnosing diagnosis. Arch. Gen. Psychiatry 1989, 46:664-667.
10. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097. EUFEST study group.
11. Kampman O., Lehtinen K., Lassila V., et al. Attitudes towards neuroleptic treatment: reliability and validity of the Attitudes towards Neuroleptic Treatment (ANT) questionnaire. Schizophr. Res. 2000, 45:223-234.
12. Kampman O., Laippala P., Väänänen J., Koivisto E., Kiviniemi P., Kilkku N., Lehtinen K. Indicators of medication compliance in first-episode psychosis. Psychiatry Res. 2002, 110:39-48.
13. Kay S.R., Opler L.A., Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) rating manual. Soc. Behav. Sci. Doc. 1986, 17:28-29.
14. Kemp R., Hayward P., Applewhaite G., Everitt B., David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996, 312:345-349.
15. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 2002, 63:892-909.
16. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.
17. McEvoy J.P., Freter S., Everett G., Geller J.L., Appelbaum P., Apperson L.J., Roth L. Insight and the clinical outcome of schizophrenic patients. J. Nerv. Ment. Dis. 1989, 177:48-51.
18. Miller R., Ream G., McCormack J., Gunduz-Bruce H., Sevy S., Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr. Res. 2009, 113:138-144.
19. Mutsatsa S.H., Joyce E.M., Hutton S.B., Webb E., Gibbins H., Paul S., Barnes T.R. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr. Scand. 2003, 108:439-446.
20. Perkins D.O. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 2002, 63:1121-1128.
21. Perkins D.O., Johnson J.L., Hamer R.M., Zipursky R.B., Keefe R.S., Centorrhino F., Green A.I., Glick I.B., Kahn R.S., Sharma T., Tohen M., McEvoy J.P., Weiden P.J., Lieberman J.A. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr. Res. 2006, 83:53-63. HGDH Research Group.
22. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A. Comparison of Atypicals in First Episode study group.Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 2008, 69:106-113.
23. Priebe S., Huxley P., Knight S., Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int. J. Soc. Psychiatry 1999, 45:7-12.
24. Rabinovitch M., Béchard-Evans L., Schmitz N., Joober R., Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can. J. Psychiatry 2009, 54:28-35.
25. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 2002, 57:209-219.
26. Sackett D.L., Haynes R.B. The architecture of diagnostic research. BMJ 2002, 324:539-541.
27. The UKU Side Effect Rating Scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatr. Scand. 1987, 76(334, suppl):81-94. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU).
28. Sheehan D.V., Lecrubier Y., Sheehan K.H., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(suppl 20):22-33.
29. van der Gaag M., Hoffman T., Remijsen M., Hijman R., de Haan L., van Meijel B., van Harten P.N., Valmaggia L., de Hert M., Cuijpers A., Wiersma D. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr. Res. 2006, 85:280-287.
30. Verdoux H., Lengronne J., Liraud F., Gonzales B., Assens F., Abalan F., van Os J. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr. Scand. 2000, 102:203-210.
31. Weiden P.J. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J. Clin. Psychiatry 2007, 68(Suppl 14):14-19.
32. Weiden P., Rapkin B., Mott T., Zygmunt A., Goldman D., Horvitz-Lennon M., Frances A. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr. Bull. 1994, 20:297-310.